EDAP TMS announces positive opinion for reimbursement from French HAS

EDAP TMS announced that the French National Authority for Health, HAS, released a favorable recommendation for the reimbursement of high-intensity focused ultrasound, HIFU, therapy in the treatment of prostate cancer. The positive opinion from HAS is an important milestone along the regulatory pathway of securing final reimbursement in France. “We are pleased to receive this positive opinion from the HAS, which we believe reflects the outstanding safety and favorable clinical outcomes from use of Focal One Robotic HIFU in the HIFI study that included more than 3,000 prostate cancer patients,” said Ryan Rhodes, Chief Executive Officer of EDAP. “Today’s decision brings us one step closer toward securing reimbursement coverage from the French Social Security authorities, as we seek to expand treatment options for physicians and their patients with our leading Focal One HIFU technology platform.”